Adam covers proteomics and the clinical lab market for GenomeWeb.
The University of Zurich spinout is using Standard BioTools' Hyperion system for its analyses and recently raised CHF 7.5 million in seed funding.
At the ASCO meeting this week, the firm will present validation data on the test, which predicts response to immune checkpoint inhibitors in advanced melanoma.
The firm is the latest iteration of the GMU spinout Theranostics Health, which has been working to drive clinical uptake of its technology for over a decade.
The firm launched last month with $40 million from Foresite Capital and GV and plans to target clonal hematopoiesis to prevent cancer and other diseases.
The assay could be useful for identifying patients who are HER2-negative by conventional IHC but who are likely to benefit from newer anti-HER2 therapies.
The single-cell omics company recently awarded $100,000 in grants funding research on its platform and published on its use for characterizing CAR-T cells.
The study identified multiple clusters of engineered natural killer T cells based on RNA-seq and found that they could be effective against the disease.
The work suggests mass spec can more accurately assess levels of immunotherapy targets like PD-L1 than conventional clinical approaches.
The firm, a spin-out of Barts Cancer Institute, is developing a mass spec-based test for identifying AML patients likely to respond to the drug midostaurin.